DLH Reports Fiscal 2021 Fourth Quarter Results
DLH Holdings Corp. (NASDAQ: DLHC) reported Q4 revenue of $65.2 million, a significant increase from $50.7 million in Q4 2020, driven by the acquisition of IBA and new contracts. For the full year, revenue reached $246.1 million, up 17.6% from $209.2 million. The company achieved earnings of $2.9 million or $0.21 per diluted share in Q4 2021, compared to $1.4 million or $0.10 in Q4 2020. Debt was reduced to $46.8 million, and total contract backlog stands at $651.5 million.
- Q4 revenue increased 28.4%, reaching $65.2 million.
- Full-year revenue rose 17.6% to $246.1 million.
- Earnings grew to $2.9 million, or $0.21 per diluted share, in Q4.
- Contract backlog increased to $651.5 million.
- Debt reduced from $70 million to $46.8 million.
- None.
Q4 Revenue of
ATLANTA, Dec. 06, 2021 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare services and solutions to federal agencies, today announced financial results for its fiscal fourth quarter ended September 30, 2021.
Highlights
- Fourth quarter revenue increased to
$65.2 million in fiscal 2021 from$50.7 million in fiscal 2020, reflecting the acquisition of Irving Burton Associates (“IBA”), new contract awards, and increased volume on existing contracts - For the full fiscal year, revenue rose to
$246.1 million from$209.2 million - Earnings were
$2.9 million , or$0.21 per diluted share, for the fiscal 2021 fourth quarter versus$1.4 million , or$0.10 per diluted share, for the fourth quarter of fiscal 2020 - Earnings for the full year were
$10.1 million , or$0.75 per diluted share, for fiscal 2021 versus$7.1 million or$0.54 per diluted share, for fiscal 2020 - Term loan reduced from
$70.0 million to$46.8 million during the fiscal year - During the fiscal fourth quarter, DLH announced several awards with an aggregate value of over
$120 million to support the Center for Disease Control and Prevention (“CDC”) and FEMA - Contract backlog was
$651.5 million as of September 30, 2021
Management Discussion
“The end of fiscal 2021 came with a few major developments that further accentuated an already standout year,” said DLH President and Chief Executive Officer Zach Parker. “We won contracts from the CDC and FEMA, which added over
“DLH continued to perform with excellence in the midst of a global pandemic. As always, I would like to thank our talented team for their many accomplishments, hard work, and dedication to taking us to the next level in terms of size and performance. Given our professional, highly-credentialed staff, many recent awards, and ongoing demand for our technology-enabled suite of services, the future is bright for DLH.”
Results for the Three Months Ended September 30, 2021
Revenue for the fourth quarter of fiscal 2021 was
Income from operations was
Interest expense was essentially flat at
For the three months ended September 30, 2021 and 2020, respectively, DLH recorded a
On a non-GAAP basis, EBITDA for the three months ended September 30, 2021 was approximately
Key Financial Indicators
Fiscal year to date, DLH generated
As of September 30, 2021, the Company had cash and cash equivalents of
At September 30, 2021, total backlog was approximately
Conference Call and Webcast Details
DLH management will discuss fourth quarter results and provide a general business update, including current competitive conditions and strategies, during a conference call beginning at 10:00 AM Eastern Time today, December 6, 2021. Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256. Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call.
A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 877-344-7529 and entering the conference ID 10149431.
About DLH
DLH delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,300 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit www.DLHcorp.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding estimates of future revenues, operating income, earnings and cash flow. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors, including: the outbreak of the novel coronavirus (“COVID-19”), including the measures to reduce its spread, and its impact on the economy and demand for our services, are uncertain, cannot be predicted, and may precipitate or exacerbate other risks and uncertainties; the risk that we will not realize the anticipated benefits of our recent or any future acquisition; the challenges of managing larger and more widespread operations; contract awards in connection with re-competes for present business and/or competition for new business; compliance with new bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the ability to successfully integrate the operations our recent acquisition and of any future acquisitions; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2021, as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.
CONTACTS:
| INVESTOR RELATIONS |
| Contact: Chris Witty |
| Phone: 646-438-9385 |
| Email: cwitty@darrowir.com |
TABLES TO FOLLOW
DLH HOLDINGS CORP.
CONSOLIDATED STATEMENTS OF INCOME
(Amounts in thousands except per share amounts)
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenue | $ | 65,182 | $ | 50,691 | $ | 246,094 | $ | 209,185 | ||||||||
| Cost of Operations: | ||||||||||||||||
| Contract costs | 51,522 | 39,701 | 194,614 | 163,596 | ||||||||||||
| General and administrative costs | 6,532 | 5,698 | 25,054 | 24,195 | ||||||||||||
| Corporate development costs | 1,088 | 930 | 1,088 | 930 | ||||||||||||
| Depreciation and amortization | 2,010 | 1,664 | 8,115 | 7,003 | ||||||||||||
| Total operating costs | 61,152 | 47,993 | 228,871 | 195,724 | ||||||||||||
| Income from operations | 4,030 | 2,698 | 17,223 | 13,461 | ||||||||||||
| Interest expense, net | 808 | 781 | 3,784 | 3,441 | ||||||||||||
| Income before income taxes | 3,222 | 1,917 | 13,439 | 10,020 | ||||||||||||
| Income tax expense | 339 | 554 | 3,294 | 2,906 | ||||||||||||
| Net income | $ | 2,883 | $ | 1,363 | $ | 10,145 | $ | 7,114 | ||||||||
| Net income per share - basic | $ | 0.23 | $ | 0.11 | $ | 0.81 | $ | 0.58 | ||||||||
| Net income per share - diluted | $ | 0.21 | $ | 0.10 | $ | 0.75 | $ | 0.54 | ||||||||
| Weighted average common shares outstanding | ||||||||||||||||
| Basic | 12,607 | 12,390 | 12,549 | 12,282 | ||||||||||||
| Diluted | 13,654 | 13,356 | 13,597 | 13,105 | ||||||||||||
DLH HOLDINGS CORP.
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands except par value of shares)
| September 30, 2021 | September 30, 2020 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 24,051 | $ | 1,357 | ||||
| Accounts receivable | 33,447 | 32,541 | ||||||
| Other current assets | 4,265 | 3,499 | ||||||
| Total current assets | 61,763 | 37,397 | ||||||
| Equipment and improvements, net | 1,912 | 3,339 | ||||||
| Operating lease right-of-use-assets | 19,919 | 22,427 | ||||||
| Deferred taxes, net | — | 37 | ||||||
| Goodwill | 65,643 | 67,144 | ||||||
| Intangible assets, net | 47,469 | 52,612 | ||||||
| Other long-term assets | 464 | 606 | ||||||
| Total assets | $ | 197,170 | $ | 183,562 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Debt obligations - current, net of deferred financing costs | $ | — | $ | 6,727 | ||||
| Operating lease liabilities - current | 2,261 | 2,045 | ||||||
| Accrued payroll | 9,125 | 10,611 | ||||||
| Deferred revenue | 22,273 | — | ||||||
| Accounts payable, accrued expenses, and other current liabilities | 32,717 | 28,578 | ||||||
| Total current liabilities | 66,376 | 47,961 | ||||||
| Long-term liabilities: | ||||||||
| Deferred taxes, net | 1,176 | — | ||||||
| Operating lease liabilities - long-term | 19,374 | 21,620 | ||||||
| Debt obligations - long-term, net of deferred financing costs | 44,636 | 60,544 | ||||||
| Total long-term liabilities | 65,186 | 82,164 | ||||||
| Total liabilities | 131,562 | 130,125 | ||||||
| Shareholders’ equity: | ||||||||
| Common stock, | 13 | 12 | ||||||
| Additional paid-in capital | 87,893 | 85,868 | ||||||
| Accumulated deficit | (22,298 | ) | (32,443 | ) | ||||
| Total shareholders’ equity | 65,608 | 53,437 | ||||||
| Total liabilities and shareholders’ equity | $ | 197,170 | $ | 183,562 | ||||
DLH HOLDINGS CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
| Twelve Months Ended | ||||||||
| September 30, | ||||||||
| 2021 | 2020 | |||||||
| Operating activities | ||||||||
| Net income | $ | 10,145 | $ | 7,114 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 8,115 | 7,003 | ||||||
| Amortization of deferred financing costs charged to interest expense | 792 | 721 | ||||||
| Stock based compensation expense | 1,660 | 910 | ||||||
| Deferred taxes, net | 1,213 | 2,308 | ||||||
| Gain from lease modification | — | (121 | ) | |||||
| Changes in operating assets and liabilities | ||||||||
| Accounts receivable | (906 | ) | (5,408 | ) | ||||
| Other current assets | (766 | ) | (1,592 | ) | ||||
| Accrued payroll | (1,486 | ) | 489 | |||||
| Deferred revenue | 22,273 | — | ||||||
| Accounts payable, accrued expenses, and other current liabilities | 4,139 | 7,188 | ||||||
| Other long-term assets and liabilities | 486 | 839 | ||||||
| Net cash provided by operating activities | 45,665 | 19,451 | ||||||
| Investing activities | ||||||||
| Business acquisition, net of cash acquired | 59 | (32,678 | ) | |||||
| Purchase of equipment and improvements | (103 | ) | (152 | ) | ||||
| Net cash used in investing activities | (44 | ) | (32,830 | ) | ||||
| Financing activities | ||||||||
| Proceeds from debt obligations | — | 33,000 | ||||||
| Repayment of debt obligations | (23,250 | ) | (19,000 | ) | ||||
| Payment of deferred financing costs | (43 | ) | (898 | ) | ||||
| Repurchased shares of common stock | — | (211 | ) | |||||
| Proceeds from issuance of common stock upon exercise of options | 366 | 55 | ||||||
| Net cash (used in)/provided by financing activities | (22,927 | ) | 12,946 | |||||
| Net change in cash and cash equivalents | 22,694 | (433 | ) | |||||
| Cash and cash equivalents at beginning of year | 1,357 | 1,790 | ||||||
| Cash and cash equivalents at end of year | $ | 24,051 | $ | 1,357 | ||||
| Supplemental disclosures of cash flow information | ||||||||
| Cash paid during the period for interest | $ | 2,941 | $ | 2,806 | ||||
| Cash paid during the period for income taxes | $ | 936 | $ | 917 | ||||
| Supplemental disclosures of non-cash activity | ||||||||
| Non-cash cancellation of common stock | $ | 68 | $ | 211 | ||||
Revenue Metrics
| Twelve Months Ended | ||||||
| September 30, | September 30, | |||||
| 2021 | 2020 | |||||
| Market Mix: | ||||||
| Defense/VA | 57 | % | 49 | % | ||
| Human Services and Solutions | 15 | % | 20 | % | ||
| Public Health/Life Sciences | 28 | % | 31 | % | ||
| Contract Mix: | ||||||
| Time and Materials | 75 | % | 70 | % | ||
| Cost Reimbursable | 20 | % | 28 | % | ||
| Firm Fixed Price | 5 | % | 2 | % | ||
| Prime vs Sub: | ||||||
| Prime | 87 | % | 92 | % | ||
| Subcontractor | 13 | % | 8 | % | ||
Non-GAAP Financial Measures
The Company uses EBITDA and EBITDA as a percent of revenue as supplemental non-GAAP measures of performance. We define EBITDA as net income excluding (i) interest expense, (ii) provision for or benefit from income taxes and (iii) depreciation and amortization. EBITDA as a percent of revenue is EBITDA for the measurement period divided by revenue for the same period.
The Company uses GAAP net income adjusted for the effect of corporate development costs as a supplemental measure of Company results. We exclude corporate development costs from this measure because they were incurred as a result of specific events, do not reflect the costs of our operations, and can affect the period-over-period assessment of operating results.
These non-GAAP measures of performance are used by management to conduct and evaluate its business during its review of operating results for the periods presented. Management and the Company’s Board utilize these non-GAAP measures to make decisions about the use of the Company’s resources, analyze performance between periods, develop internal projections and measure management performance. We believe that these non-GAAP measures are useful to investors in evaluating the Company’s ongoing operating and financial results and understanding how such results compare with the Company’s historical performance.
Reconciliation of GAAP net income to EBITDA, a non-GAAP measure (in thousands):
| Three Months Ended | Twelve Months Ended | |||||||||||||||||
| September 30, | September 30, | |||||||||||||||||
| 2021 | 2020 | Change | 2021 | 2020 | Change | |||||||||||||
| Net income | $ | 2,883 | $ | 1,363 | $ | 1,520 | $ | 10,145 | $ | 7,114 | $ | 3,031 | ||||||
| (i) Interest expense, net | 808 | 781 | 27 | 3,784 | 3,441 | 343 | ||||||||||||
| (ii) Provision for taxes | 339 | 554 | (215) | 3,294 | 2,906 | 388 | ||||||||||||
| (iii) Depreciation and amortization | 2,010 | 1,664 | 346 | 8,115 | 7,003 | 1,112 | ||||||||||||
| EBITDA | $ | 6,040 | $ | 4,362 | $ | 1,678 | $ | 25,338 | $ | 20,464 | $ | 4,874 | ||||||
| Net income as a % of revenue | ||||||||||||||||||
| EBITDA as a % of revenue | ||||||||||||||||||
| Revenue | $ | 65,182 | $ | 50,691 | $ | 14,491 | $ | 246,094 | $ | 209,185 | $ | 36,909 | ||||||
Reconciliation of GAAP net income to net income adjusted for the effect of the corporate development costs, a non-GAAP measure (in thousands except for per share amounts):
| Year Ended | ||||||||||||
| September 30, | ||||||||||||
| 2021 | 2020 | Change | ||||||||||
| Net income | $ | 10,145 | $ | 7,114 | $ | 3,031 | ||||||
| Corporate development costs | 1,088 | 930 | 158 | |||||||||
| Tax effect of excluding corporate development costs | (267 | ) | (270 | ) | 3 | |||||||
| Net income adjusted for corporate development costs | $ | 10,966 | $ | 7,774 | $ | 3,192 | ||||||
| Net income per diluted share | $ | 0.75 | $ | 0.54 | $ | 0.21 | ||||||
| Impact of corporate development costs, net | 0.06 | 0.05 | 0.01 | |||||||||
| Net income per diluted share adjusted for corporate development costs | $ | 0.81 | $ | 0.59 | $ | 0.22 | ||||||
FAQ
What were DLHC's Q4 2021 financial results?
How much did DLHC earn in fiscal year 2021?
What is DLHC's current debt position?
What is the contract backlog for DLHC?
What drove the growth in DLHC's Q4 revenue?
